Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1983 May;40(2):622–628. doi: 10.1128/iai.40.2.622-628.1983

Activation of macrophages by quinonyl-N-acetylmuramyl dipeptide.

I Saiki, Y Tokushima, K Nishimura, Y Yamamura, I Azuma
PMCID: PMC264899  PMID: 6840857

Abstract

The effect of 6-O-QS-10-N-acetylmuramyl-L-valyl-D-isoglutamine methyl ester (quinonyl-MDP-66) on various functions of macrophages was examined. Mouse peritoneal macrophages, when treated either in vitro or in vivo with quinonyl-MDP-66 suspended in phosphate-buffered saline, showed a capacity for cytolysis and cytostasis against tumor targets and released H2O2 in the presence of phorbol myristate acetate. The macrophages induced by quinonyl-MDP-66 also had both antibody-dependent cell-mediated cytotoxicity and phagocytic activity against erythroid targets. The fact that synthetic quinonyl-MDP-66 stimulates the macrophages to become more cytotoxic than do other MDP analogs suggests that the lipophilic residue (QS-10) in quinonyl-MDP-66 may be important for the development of this activity.

Full text

PDF
622

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adam A., Ciorbaru R., Ellouz F., Petit J. F., Lederer E. Adjuvant activity of monomeric bacterial cell wall peptidoglycans. Biochem Biophys Res Commun. 1974 Feb 4;56(3):561–567. doi: 10.1016/0006-291x(74)90640-8. [DOI] [PubMed] [Google Scholar]
  2. Adam A., Devys M., Souvannavong V., Lefrancier P., Choay J., Lederer E. Correlation of structure and adjuvant activity of N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP), its derivatives and analogues. Anti-adjuvant and competition properties of stereoisomers. Biochem Biophys Res Commun. 1976 Sep 7;72(1):339–346. doi: 10.1016/0006-291x(76)90999-2. [DOI] [PubMed] [Google Scholar]
  3. Adams D. O., Johnson W. J., Fiorito E., Nathan C. F. Hydrogen peroxide and cytolytic factor can interact synergistically in effecting cytolysis of neoplastic targets. J Immunol. 1981 Nov;127(5):1973–1977. [PubMed] [Google Scholar]
  4. Azuma I., Sugimura K., Yamawaki M., Uemiya M., Kusumoto S., Okada S., Shiba T., Yamamura Y. Adjuvant activity of synthetic 6-O-"mycoloyl"-N-acetylmuramyl-L-alanyl-D-isoglutamine and related compounds. Infect Immun. 1978 Jun;20(3):600–607. doi: 10.1128/iai.20.3.600-607.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Azuma I., Yamawaki M., Uemiya M., Saiki I., Tanio Y., Kobayashi S., Fukuda T., Imada I., Yamamura Y. Adjuvant and antitumor activities of quinonyl-N-acetylmuramyldipeptides. Gan. 1979 Dec;70(6):847–848. [PubMed] [Google Scholar]
  6. Chedid L., Audibert F., Johnson A. G. Biological activities of muramyl dipeptide, a synthetic glycopeptide analogous to bacterial immunoregulating agents. Prog Allergy. 1978;25:63–105. [PubMed] [Google Scholar]
  7. Chedid L., Parant M., Parant F., Lefrancher P., Choay J., Lederer E. Enhancement of nonspecific immunity to Klebsiella pneumoniae infection by a synthetic immunoadjuvant (N-acetylmuramyl-L-alanyl-D-isoglutamine) and several analogs. Proc Natl Acad Sci U S A. 1977 May;74(5):2089–2093. doi: 10.1073/pnas.74.5.2089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cohen M. S., Taffet S. M., Adams D. O. The relationship between competence for secretion of H2O2 and completion of tumor cytotoxicity by BCG-elicited murine macrophages. J Immunol. 1982 Apr;128(4):1781–1785. [PubMed] [Google Scholar]
  9. Ellouz F., Adam A., Ciorbaru R., Lederer E. Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun. 1974 Aug 19;59(4):1317–1325. doi: 10.1016/0006-291x(74)90458-6. [DOI] [PubMed] [Google Scholar]
  10. Germain R. N., Williams R. M., Benacerraf B. Specific and nonspecific antitumor immunity. II. Macrophage-mediated nonspecific effector activity induced by BCG and similar agents. J Natl Cancer Inst. 1975 Mar;54(3):709–720. [PubMed] [Google Scholar]
  11. Haskill J. S., Fett J. W. Possible evidence for antibody-dependent macrophage-mediated cytotoxicity directed against murine adenocarcinoma cells in vivo. J Immunol. 1976 Nov;117(5 PT2):1992–1998. [PubMed] [Google Scholar]
  12. Juy D., Chedid L. Comparison between macrophage activation and enhancement of nonspecific resistance to tumors by mycobacterial immunoadjuvants. Proc Natl Acad Sci U S A. 1975 Oct;72(10):4105–4109. doi: 10.1073/pnas.72.10.4105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Key M., Haskill S. Macrophage-mediated, antibody-dependent destruction of tumor cells in DBA/2 mice: in vitro identification of an in situ mechanism. J Natl Cancer Inst. 1981 Jan;66(1):103–110. [PubMed] [Google Scholar]
  14. Kobayashi S., Fukuda T., Imada I., Fujino M., Azuma I., Yamamura Y. Novel quinonyl derivatives of muramyl dipeptide possessing potent antitumor activity. Chem Pharm Bull (Tokyo) 1979 Dec;27(12):3193–3196. doi: 10.1248/cpb.27.3193. [DOI] [PubMed] [Google Scholar]
  15. Koren H. S., Anderson S. J., Adams D. O. Studies on the antibody-dependent cell-mediated cytotoxicity (ADCC) of thioglycollate-stimulated and BCG-activated peritoneal macrophages. Cell Immunol. 1981 Jan 1;57(1):51–61. doi: 10.1016/0008-8749(81)90119-2. [DOI] [PubMed] [Google Scholar]
  16. Kotani S., Watanabe Y., Kinoshita F., Shimono T., Morisaki I. Immunoadjuvant activities of synthetic N-acetyl-muramyl-peptides or -amino acids. Biken J. 1975 Jun;18(2):105–111. [PubMed] [Google Scholar]
  17. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  18. Leclerc C., Juy D., Bourgeois E., Chedid L. In vivo regulation of humoral and cellular immune responses of mice by a synthetic adjuvant, N-acetyl-muramyl-L-alanyl-D-isoglutamine, muramyl dipeptide for MDP. Cell Immunol. 1979 Jun;45(1):199–206. doi: 10.1016/0008-8749(79)90377-0. [DOI] [PubMed] [Google Scholar]
  19. Nathan C. F., Brukner L. H., Silverstein S. C., Cohn Z. A. Extracellular cytolysis by activated macrophages and granulocytes. I. Pharmacologic triggering of effector cells and the release of hydrogen peroxide. J Exp Med. 1979 Jan 1;149(1):84–99. doi: 10.1084/jem.149.1.84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Nathan C. F., Cohn Z. A. Antitumor effects of hydrogen peroxide in vivo. J Exp Med. 1981 Nov 1;154(5):1539–1553. doi: 10.1084/jem.154.5.1539. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Nathan C. F., Silverstein S. C., Brukner L. H., Cohn Z. A. Extracellular cytolysis by activated macrophages and granulocytes. II. Hydrogen peroxide as a mediator of cytotoxicity. J Exp Med. 1979 Jan 1;149(1):100–113. doi: 10.1084/jem.149.1.100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Pabst M. J., Cummings N. P., Shiba T., Kusumoto S., Kotani S. Lipophilic derivative of muramyl dipeptide is more active than muramyl dipeptide in priming macrophages to release superoxide anion. Infect Immun. 1980 Aug;29(2):617–622. doi: 10.1128/iai.29.2.617-622.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Pabst M. J., Johnston R. B., Jr Increased production of superoxide anion by macrophages exposed in vitro to muramyl dipeptide or lipopolysaccharide. J Exp Med. 1980 Jan 1;151(1):101–114. doi: 10.1084/jem.151.1.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Pick E., Mizel D. Rapid microassays for the measurement of superoxide and hydrogen peroxide production by macrophages in culture using an automatic enzyme immunoassay reader. J Immunol Methods. 1981;46(2):211–226. doi: 10.1016/0022-1759(81)90138-1. [DOI] [PubMed] [Google Scholar]
  25. Saiki I., Kamisango K., Tanio Y., Okumura H., Yamamura Y., Azuma I. Adjuvant activity of purified peptidoglycan of Listeria monocytogenes in mice and guinea pigs. Infect Immun. 1982 Oct;38(1):58–65. doi: 10.1128/iai.38.1.58-65.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Saiki I., Tanio Y., Yamamoto K. I., Yamamura Y., Azuma I. Effect of quinonyl-N-acetyl muramyl dipeptide on immune responses in tumor-bearing mice. Infect Immun. 1983 Jan;39(1):137–141. doi: 10.1128/iai.39.1.137-141.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Saiki I., Tanio Y., Yamawaki M., Uemiya M., Kobayashi S., Fukuda T., Yukimasa H., Yamamura Y., Azuma I. Adjuvant activities of quinonyl-N-acetyl muramyl dipeptides in mice and guinea pigs. Infect Immun. 1981 Jan;31(1):114–121. doi: 10.1128/iai.31.1.114-121.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Scornik J. C., Klein P. A. Antibody-dependent lysis of tumor cells in vivo. I. Early lysis of tumor cells. J Natl Cancer Inst. 1978 Oct;61(4):1143–1148. [PubMed] [Google Scholar]
  29. Scornik J. C., Klein P. A. Antibody-dependent lysis of tumor cells in vivo. II. Elimination of chromium-51 as a measurement of cytolysis. J Natl Cancer Inst. 1978 Oct;61(4):1149–1154. [PubMed] [Google Scholar]
  30. Shaw D. R., Griffin F. M., Jr Thioglycollate-elicited mouse peritoneal macrophages are less efficient than resident macrophages in antibody-dependent cell-mediated cytolysis. J Immunol. 1982 Jan;128(1):433–440. [PubMed] [Google Scholar]
  31. Taniyama T., Holden H. T. Direct augmentation of cytolytic activity of tumor-derived macrophages and macrophage cell lines by muramyl dipeptide. Cell Immunol. 1979 Dec;48(2):369–374. doi: 10.1016/0008-8749(79)90131-x. [DOI] [PubMed] [Google Scholar]
  32. Walker W. S., Demus A. Antibody-dependent cytolysis of chicken erythrocytes by an in vitro-established line of mouse peritoneal macrophages. J Immunol. 1975 Feb;114(2 Pt 2):765–769. [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES